![]() "Connected Insights complements our suite of NGS solutions to generate, analyze, annotate, and interpret data consistently-today and into the future." "We're seeing growing demand for NGS testing in health care systems, and with that comes the need for interpretation of large genomic data sets with complex health implications in a landscape of frequently changing guidelines and drug approvals," said Rami Mehio, head of global software and informatics at Illumina. The product is undergoing beta testing in the US. Connected Insights is commercially available in a limited number of countries. Ultimately it is designed to support a diverse range of applications, soon including whole-genome sequencing (WGS) for rare disease. ![]() The initial release will support somatic oncology applications, coinciding with the increasing use of comprehensive genomic profiling (CGP) for advanced tumors. Expanding on Illumina's Connected Software portfolio, Connected Insights is designed to streamline interpretation and reporting from a range of assay types, enabling labs to scale use of NGS and reduce turnaround time of clinical reporting via integration of third-party knowledge bases. ![]()
0 Comments
Leave a Reply. |